The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.

about

The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q38709347

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.

@en

type

Item

label

The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.

@en

prefLabel

The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.

@en

P1476

The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.

@en

P2093

Johannes Ettl

http://www.w3.org/2001/XMLSchema#string

Nadia Harbeck

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis

CDK-independent activation of estrogen receptor by cyclin D1

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

ABC3 Consensus: Assessment by a German Group of Experts

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

P304

661-668

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1347506

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28649895

http://www.w3.org/2001/XMLSchema#string